Eli Lilly's Omvoh shows long-term remission and improved quality of life for ulcerative colitis patients in new trial results ...

Eli Lilly’s Omvoh (mirikizumab-mrkz) has shown continued benefit after four years in a Phase III open-label extension trial ...

The FDA-approved Inluriyo, an oral estrogen receptor antagonist from Eli Lilly, has shown to achieve significant improvement ...

Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity ...

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Inluriyo (imlunestrant) to treat advanced or metastatic ...

Herantis Pharma announces positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease Trial meets all primary ...

Herantis Pharma is developing HER-096, a first-in-class drug candidate with the potential to stop the progression of Parkinson’s disease, repair striatal damage and significantly improve both an ...

Novo Nordisk A/S faces competition in obesity drug development space; pipeline innovations & long-term outlook. Read why NVO ...

Regeneron’s monoclonal antibody trevogrumab, with or without the anti-activin A antibody garetosmab, appears to preserve lean ...

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Eli Lilly for Inluriyo™ (imlunestrant), indicated for the treatment of adults with estrogen ...

After tanking in early August, the world’s most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company (NYSE: LLY), the maker of the wildly popular weight ...

Earlier this year at the American Society of Clinical Oncology (ASCO) Congress, pharmaphorum spoke with Redwood City, ...